Company: CDLX
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001666071-25-000126
Chunk: 103

Company: Cardlytics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 103
---
 — — 8,326 Settlement of restricted stock556 — — — — — Issuance of common stock pursuant to the 2018 ESPP (as defined below)263 — 447 — — 447 Other comprehensive loss— — — (4,874)— (4,874)Net Loss— — — — (9,283)(9,283)Balance – June 30, 202552,994 $10 $1,385,465 $(3,628)$(1,323,141)$58,706 

See notes to the condensed consolidated financial statements6

Six Months Ended June 30, 2024:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncomeAccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202339,728 $9 $1,243,594 $2,467 $(1,111,272)$134,798 Exercise of common stock options3 — 5 — — 5 Stock-based compensation— — 26,099 — — 26,099 Settlement of restricted stock1,929 — — — — — Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)3,592 — 27,451 — — 27,451 Issuance of common stock, net of issuance costs - ATM Offering Program (as defined below)3,908 — 48,151 — — 48,151 Issuance of common stock pursuant to the 2018 ESPP (as defined below)242 — 1,461 — — 1,461 Termination of capped calls related to 2020 Convertible Senior Notes— — 115 — — 115 Other comprehensive income— — — 486 — 486 Net Loss— — — — (28,532)(28,532)Balance – June 30, 202449,402 $9 $1,346,876 $2,953 $(1,139,804)$210,034 

Three Months Ended June 30, 2024:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensiveIncomeAccumulatedDeficit